Sigma Healthcare Faces Earnings Scrutiny Amidst High Valuation
Sigma Healthcare (ASX:SIG), the company behind the ubiquitous Chemist Warehouse brand, is poised to release its financial results on February 26th. Investors will be keenly observing whether the company’s underlying performance can justify its current, seemingly lofty, stock valuation. The past year has seen Sigma shares climb approximately 11%, a notable outlier when compared to the broader ASX 200 healthcare sector’s 25% decline, while the overall market has remained relatively stagnant.
This performance has led some analysts, like those at Bell Potter, to label Sigma as a “standout performer.” However, since the merger with Chemist Warehouse a year ago, Sigma has been relatively quiet in terms of ASX announcements. The last significant update came from the company’s October Annual General Meeting, preceded by the announcement of a new CEO in August.
Bell Potter highlights that even minor fluctuations in gross profit margin could significantly impact the upcoming results. The firm noted that the pro forma 2024-25 result’s gross profit margin of 17.7% exceeded expectations. The December half-year report will be the first full six-month period encompassing the consolidated group and will include the crucial Christmas trading period. Therefore, margin analysis, alongside movements in operating expenses, will be critical in determining full-year earnings.
Chemist Warehouse Expansion and Market Saturation
The growth in Chemist Warehouse’s store network has been a primary driver of sales and earnings. The familiar yellow and red branding adorns 894 outlets across Australia and an additional 88 stores internationally. However, Bell Potter suggests that the Australian chemist market may be approaching saturation, making network expansion increasingly challenging year on year.
For the interim period, Bell Potter forecasts Sigma to report revenue of $5,257 million, a 7% increase, and underlying earnings of $495 million, up 16%. These figures are more conservative than the market consensus, which anticipates $574 million. Sigma currently trades at a price-to-earnings multiple of 40-50 times current year earnings, with a dividend yield of 1.4%. Bell Potter maintains a “hold” rating with a target price of $3, viewing Sigma as a “safe haven for investors despite it being expensive relative to retail peers.” In contrast, broker Morgans has issued a “buy” recommendation with a valuation of $3.39, though they point out that trans-Tasman competitor EBOS Group (ASX:EBO) offers a more attractive valuation.
Memphasys Receives Timely TGA Approval for Sperm Separation Device
Memphasys (ASX:MEM) has secured a significant boost with the Therapeutic Goods Administration (TGA) granting approval for its Felix sperm separation device, two months ahead of the anticipated timeline. This approval enables the immediate commercial sale and clinical deployment of Felix across Australia, targeting IVF clinics.
The Felix device is designed to offer a gentler and more effective method for identifying viable sperm for IVF procedures. The TGA registration is expected to substantially de-risk the near-term commercialisation pathway, accelerating the time to market and bringing forward revenue generation. Felix had previously received European Union assent in late December. Memphasys has been in discussions with potential partners for the Australian market, which is considered strategically important and accounts for approximately 60,000 fresh IVF cycles annually.
Truscreen Expands Global Reach for Cervical Cancer Detection Tool
Truscreen Group (ASX:TRU), developers of a portable, lab-free cervical cancer detection device, has reported that its China operations are on track to meet sales forecasts for the year ending March 2026. The Truscreen device identifies cervical tissue abnormalities through real-time optical and electrical stimuli, incorporating AI capabilities.
China, being Truscreen’s most established and largest market, provides a strong foundation for growth. The company anticipates significant contributions from other key markets, including India and Indonesia, the world’s most and fourth most populous nations, respectively, as well as Mexico and Vietnam. Looking further ahead, South Africa, Nigeria, Rwanda, and Eswatini are expected to contribute from the 2026-27 financial year.
In Zimbabwe, Truscreen aims to screen over 20,000 women in the 2026 calendar year. The company has also solidified its presence in Central Asia, signing its first sales contract for Uzbekistan, involving the sale of eight devices and 8,280 single-use sensors for public screening programs. An additional 18 devices and 3,240 sensors have been sold to its Central Asian distributor, supporting screening programs in Kyrgyzstan, Kazakhstan, Armenia, and Belarus, which collectively have a screening-age female population exceeding 12 million.
Paradigm Biopharmaceuticals Shifts Focus to Animal Health with New Licensing Agreement
Paradigm Biopharmaceuticals (ASX:PAR) is venturing into the animal health sector with a new licensing and supply agreement with Avet Health. This collaboration will focus on developing a combination oral therapy for osteoarthritis (OA) in animals, building on Paradigm’s existing research into pentosan polysulphate sodium.
Avet Health will secure exclusive rights for the Australian and New Zealand markets, with first dibs on all other territories except the United States. Paradigm stands to gain up to $1 million in development milestones and potential sales royalties of up to 20%. This partnership offers a non-dilutive approach for Paradigm to advance its animal health initiatives while maintaining its primary focus on its pivotal Phase III human knee OA trial.
Imricor Pursues Third FDA Clearance for Cardiac Mapping System
Imricor Medical Systems (ASX:IMR) is seeking its third US Food and Drug Administration (FDA) clearance for a cardiac product with the submission of its Advantage electrophysiology (EP) mapping system. Imricor, based in Burnsville, Minnesota, has pioneered the world’s first guided ablation catheter designed for use with magnetic resonance imaging (MRI), an alternative to traditional X-ray fluoroscopy.
The FDA granted clearance for Imricor’s Vision-MR catheter in mid-January, followed by the approval of its Northstar 3D mapping and guidance system in late January. The Advantage-MR system is crucial for clinicians performing electrophysiological studies and ablations, enabling them to acquire, amplify, filter, digitise, display, and record electrical signals from the heart with high fidelity. Head of the company, Steve Wedan, stated that the Advantage-MR was developed to address the challenges of recording “clean” electrical signals that rival systems struggle to achieve, effectively integrating all components of Imricor’s cardiac intervention technology.
